AgriTech Company Sells to Organic and Cannabis Markets

  ()
The company's soon-to-be-announced prefeasibility study will evaluate expansion plans. read more >

Streaming Company's 'Attractive Valuation' Is Behind Analyst's Outperform Rating

Research Report
  ()
BMO Capital Markets reviewed this company's Q3/17 financial results and an impending deadline pertaining to one of its streams. read more >

Could Your Car Be Hacked? This Micro-Cap May Have the Solution

Contributed Opinion
  ()
The many computer connections in cars make them vulnerable to hacking, says Michael Sheikh, founder of Falcon Strategic Research, who profiles a small company whose software takes a radically different approach to cybersecurity. read more >

Three Resource Companies; One Good Buy

Contributed Opinion
  ()
Adrian Day of Adrian Day Asset Management reviews the current news and prospects at three resource companies, and comes up with at least one good buy. read more >

Biotech Targets 'Blockbuster' Markets; Less-Addictive Opioid Painkiller Set for FDA Filing

Contributed Opinion
  ()
Medical Technology Stock Letter editor John McCamant outlines the reasons behind the buy rating and target price increases for a company that, in addition to developing an alternative to addictive opioids for pain relief, has candidates targeting multiple immune disorders and cancer. read more >

Biotech's Target Price Increased as Shares 'Deeply Undervalued'

Research Report
  ()
Wedbush analyst Robert Driscoll provided an update on the lead asset of this drug developer targeting cancer. read more >

The Lowdown on Getting High in Canada

Contributed Opinion
  ()
Some 600 tonnes of marijuana a year are up for grabs as Canada moves to legalize weed, says Rick Mills, founder of Ahead of the Herd, who puts forth his case on why cannabis stocks should be in every investor's portfolio. read more >
Expert Investing Ideas

"We continue to believe PVG remains undervalued."

–Joe Reagor, ROTH Capital Partners


"KDX's Q3/17 revenue came in at $48.9M."

–Steve King, M Partners


"In Q3/17, WPM showed improvements in production relative to Q2/17."

–Charles Gibson, Edison Investment Research


"Much of the heavy lifting is now behind KDX."

–Jake Sekelsky, ROTH Capital Partners


"WPM reported an in line Q3/17; adjusted EPS was $0.15."

–Andrew Kaip, BMO Capital Markets


The Silver and Gold Summit

Get Our Streetwise Reports Newsletter Free

A valid email address is required to subscribe

The Holiday Season Comes Early After an Updated PEA Brings In a Bundle Full of Buy Ratings for Precious Metals Explorer

  ()
Five analysts explain why "several significant improvements" led to their Buy recommendations and highlight what investors need to know. read more >

Uranium Production Cuts 'Very Positive' for Market

Research Report
  ()
Rob Chang, an analyst with Cantor Fitzgerald, discussed how one uranium company's upcoming facility closures should affect the market. read more >

Two 'Low-Risk' Gold Companies Present Opportunities to Buy and Hold

Contributed Opinion
  ()
In his latest dispatch, Adrian Day of Adrian Day Asset Management reflects on the prospects and performance of a pair of gold companies. read more >

Analyst Says Biotech Share Price Could Potentially 'Double'

Research Report
  ()
Analyst Grant Zeng of Zacks Small Cap Research examines what transpired with this biopharmaceutical company during Q3/17. read more >
The Silver and Gold Summit